Molecular Profiles has opened its new facility in Nottingham following a successful MHRA inspection. The £9 million, 30,000-sq.-ft. pharmaceutical production facility will provide clinical manufacturing capabilities designed to handle a range of non-sterile dosage forms such as solids, liquids, semi-solids and inhaled products. The investment adds six GMP suites, new labs, and a dedicated clinical packing area to support Phase I and II clinical trials. The facility also allows for the manufacture of highly potent compounds up to OEB 4 level with manufacturing batch scale of up to 30kg.
Nikin Patel, chief executive officer of Molecular Profiles, said, “Receiving our license from the MHRA for our new site is probably the biggest milestone for our business since we set-up shop so is naturally a very exciting time for everyone involved. From a commercial perspective, we are very much open for business and have already received significant interest from companies looking to use our manufacturing capabilities to assist with their clinical trial requirements."
The company's new vice president Steve Kemp added, “We have enjoyed a sustained and gradual period of growth over the last decade driven by our consulting, formulation development and analytical services but we are expecting our expanded manufacturing facilities to take us to the next level by helping us better compete on a global scale.”